Lawitz 2010a

Methods	Randomised clinical trial
Participants	54 participants Country: USA Inclusion criteria: Adult treatment‐naive participants in genotype 1 HCV participants.
Interventions	Experimental group: oral 25 mg, 75 mg, or 200 mg of GS‐9256 twice daily, or 300 mg of GS‐9256 once daily for 3 days. Control group: placebo.
Outcomes	Safesty assessment, HCV RNA level, pharmacokinetics.
Notes	We emailed Lawitz and colleagues on 26 April 2016 for additional information on random, blinding, missing data, protocol, data, participants characteristics, funding, number of participants in placebo/exp group but reply not received yet.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Described as double‐blinded, but it was not described how blinding was performed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Described as double‐blinded, but it was not described how blinding was performed
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained
Vested‐interest bias	High risk	Several authors worked for Gilead Sciences
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias